Navigation Links
Rhinitis in Medical Technology

Stallergenes S.A.: Positive Results From a Phase IIb/III Clinical Trial on the House Dust Mite Desensitization Tablet

... from moderate to severe persistent allergic rhinitis to house dust mites, including 509 patients, over ... conduct of clinical trials in perennial allergic rhinitis is a major challenge. The outcomes of the VO57.07 ... therapy". About House Dust Mites Allergic rhinitis In Europe, on average, almost 40% of ...

Morria Biopharmaceuticals Plc Announces the Initiation of a Phase II Clinical Multi-dose Study of MRX-4 in Allergic Rhinitis

... in 105 patients suffering from allergic rhinitis (AR). The two-arm, randomized, ... this data." ABOUT ALLERGIC RHINITIS Allergic rhinitis is a common condition that affects nearly 59 ... with a market of close to $4 billion. Allergic rhinitis is characterized by inflammation of the nasal ...

New Survey Suggests Cultural Ambivalence to Allergies Leaves Many Suffering Needlessly

... . About Allergic Rhinitis Allergic rhinitis affects more than 50 million people in the ... seasonal and perennial. Seasonal allergic rhinitis (often referred to as "hay-fever") occurs ... grass and weed pollen. Perennial allergic rhinitis can occur throughout the year and is caused by ...

FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria

... allergy relief." Studies in allergic rhinitis patients demonstrated ... people in the United States. Seasonal allergic rhinitis (SAR), commonly referred to as "hay fever" or ... weeds, as well as mold. Perennial Allergic rhinitis (PAR) is sometimes referred to as "year round" or ...

Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients

... of MRX-4 in 16 patients suffering from allergic rhinitis (AR). MRX-4 was nasally administered as a ... challenge. ABOUT ALLERGIC RHINITIS Allergic rhinitis is a common condition that affects nearly 59 ... with a market of close to $4 billion. Allergic rhinitis is characterized by inflammation of the nasal ...

New Data Shows Veramyst Effectively Treats Symptoms of Perennial Allergic Rhinitis

... ocular allergy symptoms of perennial allergic rhinitis (PAR) in patients 12 years of age and older, ... of symptoms of seasonal and perennial allergic rhinitis in adults and in children age two years and ... 12 years of age and older with perennial allergic rhinitis who were treated with Veramyst 110 mcg once daily ...

Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis

... scientific advisory board member. ABOUT ALLERGIC rhinitis Allergic rhinitis is a common condition that affects nearly 59 ... with a market of nearly $4 billion. Allergic rhinitis is characterized by inflammation of the nasal ...

STALLERGENES: Oralair(R) Grasses Obtains a Pediatric MA(1) in Germany

... grass pollens, the allergen that causes rhinoconjunctivitis and allergic rhinitis in more than 50% of patients in Europe. With a safe and easy-to-use ... Nearly 15 to 20% of these patients suffer from moderate to severe allergic rhinitis and rhinoconjunctivitis, not controlled by their usual medical treatment. ...

Circassia Initiates Further Phase II Clinical Study of Toleromune(R) Anti-Allergy Technology

... treatment, and will then complete a questionnaire to score their allergic rhinitis symptoms. This will allow investigators to evaluate the impact of the ... market opportunities. Over 150 million people suffer from allergic rhinitis in the US and Europe and the market for current treatments is ...

Morria Biopharmaceuticals Plc Announces Regulatory Approval to Commence Phase II Clinical Study of MRX-4 in Allergic Rhinitis

... dollar allergic rhinitis market". ABOUT ALLERGIC RHINITIS Allergic rhinitis is a common condition that affects nearly 59 million people in the United ... percent of the population) with a market of close to $4 billion. Allergic rhinitis is characterized by inflammation of the nasal membranes accompanied by ...

New Trial Presented at AAAAI Reports that the Growth of Children 2-5 Years Old with Year-Round Allergic Rhinitis Continued According to Normal Age-Adjusted Distribution Over a 6-Month Treatment with Nasacort AQ

... corticosteroids in the treatment of very young children with allergic rhinitis has in the past raised concerns regarding potential effects on growth," ... growth charts were updated in 2000. About Allergic Rhinitis Allergic rhinitis is a swelling of the nasal passages, usually accompanied by sneezing, ...

Dynavax Presents New Analysis of TOLAMBA(TM) Data at ACAAI Meeting

... analysis of patients in the Midwest showed a correlation between higher rhinitis symptoms in the placebo group and measurable efficacy in the ... group overall did not demonstrate sufficient levels of ragweed allergic rhinitis and as a result, no meaningful clinical effect could be measured. ...

DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD

... the early 1970s as the active pharmaceutical ingredient in a nasal spray and in a metered-dose inhaler for the treatment of patients with allergic rhinitis and asthma. orBec(R) is formulated for oral administration as a single product consisting of two tablets; one tablet is intended to release BDP in ...

Circassia Begins Phase II Clinical Trial With Ragweed Allergy Therapy

... benefits compared with existing therapies, and consequently have significant market opportunities. Over 150 million people suffer from allergic rhinitis in the US and Europe, and the current treatment market is approximately $12 billion per year. ToleroMune technology has additional potential ...

Circassia's Allergy Therapy Begins Phase II Clinical Trial in Asthma Patients

... benefits compared with existing therapies, and consequently have significant market opportunities. Over 150 million people suffer from allergic rhinitis in the US and Europe, and the market for current treatments is approximately $12 billion per year. The prevalence of cat allergies is also high, with ...

Meritage Pharma Initiates Phase 2b Clinical Trial of Oral Viscous Budesonide for Pediatric Patients With Eosinophilic Esophagitis

... in several products approved by the U.S. Food and Drug Administration (FDA), including products for the treatment of pediatric asthma, allergic rhinitis and Crohn's disease. Budesonide is a corticosteroid and has an established safety profile in those diseases. It works by decreasing inflammation in ...

ISTA Pharmaceuticals' New Drug Application for Bepreve(TM) Accepted for Review by U.S. Food and Drug Administration

... the signs and symptoms of allergic conjunctivitis. Bepotastine was approved in Japan for use as a systemic drug in the treatment of allergic rhinitis and urticaria/pruritus in July 2000 and January 2002, respectively, and is marketed by Mitsubishi Tanabe Pharma Corporation (formerly Tanabe Seiyaku ...

Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment

... exposure chamber both before and after receiving the study treatment. During these "challenges" the volunteers will monitor and record their allergic rhinitis symptoms to allow investigators to assess the effect of the ToleroMune treatment. "We are delighted that this trial is making such rapid ...

Colesevelam HCl Lowered LDL Cholesterol in Pediatric Patients With Heterozygous Familial Hypercholesterolemia

... in the eight-week, doubleblind period were: nasopharyngitis (6.2 percent), headache (4.7 percent), fatigue (3.9 percent), vomiting (2.3 percent), rhinitis (2.3 percent) and creatine phosphokinase increase (2.3 percent). The most frequently reported adverse reactions during the additional 18-week ...

Circassia Achieves Successful Phase II Clinical Results With Toleromune(R) Anti-Allergy Technology

... benefits, Circassia's anti-allergy products would have significant market opportunities. Currently, over 150 million people suffer from allergic rhinitis in the US and Europe and the market for current treatments, despite their limitations, is approximately $12 billion per year. The prevalence ...

ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing

... the signs and symptoms of allergic conjunctivitis. Bepotastine was approved in Japan for use as a systemic drug in the treatment of allergic rhinitis and urticaria/pruritus in July 2000 and January 2002, respectively, and is marketed by Mitsubishi Tanabe Pharma Corporation (formerly Tanabe Seiyaku ...

Study Says Allergy Shots Help Children, Reduce Health Care Costs

... reduces health care costs, even when the appropriate course of treatment is not completed. The study of 520 low-income Florida children with allergic rhinitis found that IT was associated with significant savings across all aspects of the health care system -- inpatient, outpatient and medication treatments ...

Placebo-controlled Phase IIa Study with the Immunotherapeutic CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in Hay Fever Patients

... suffering from mild to moderate seasonal allergic rhinitis due to grass pollen allergy. Upon entry into the ... (WHO, 2002). Seasonal allergic rhinitis due to grass pollen (commonly known as hay fever) ... a condition due to allergy that mimics a cold. rhinitis means "inflammation of the nasal ...

Positive results from placebo-controlled phase IIa study in patients suffering from house dust mite allergy

... patients suffering from mild to moderate allergic rhinitis due to house dust mite allergy and assessed in a ... from mild to moderate perennial allergic rhinitis due to house dust mite allergy. Upon entry into ... in clinical trials for the treatment of allergic rhinitis and atopic dermatitis. About allergic diseases ...

Inspire Announces Positive Results of Phase 2 Trial of Epinastine Nasal Spray for Seasonal Allergic Rhinitis

... placebo in 569 subjects who had a documented history of seasonal allergic rhinitis to mountain cedar pollen. Of the subjects randomized in the trial, 95% ... Drug Administration's (FDA) draft guidance document for seasonal allergic rhinitis and includes runny nose, nasal congestion, itchy nose and sneezing. ...

Inflazyme Announces Outcome of Review of Phase 2b Asthma Study: Potential Mitigating Factors Identified which Prevent Clear Interpretation of Results

... and the patients’ allergies might have diminished during the treatment phase of the trial as the allergy season waned. Resolution of allergic rhinitis could improve asthma symptoms and other measures of asthma control in all patients independent of treatment. Our Phase 2b study was of a standard ...

Pacgen Announces Positive Results from Phase I/II Trial of Novel Antifungal Drug

... with cellular immune deficiency states, such as HIV and AIDS. Patients with xerostomia and those treated with inhaled corticosteroids for asthma or rhinitis are also at risk. Oropharyngeal candidiasis infection can cause great discomfort, and if not treated, can spread from the primary site of ...

ISTA Pharmaceuticals Announces Statistically Significant Preliminary Results From its U.S. Phase II/III Clinical Study Of Bepotastine

... market size was approximately $500 million. Bepotastine was approved in Japan for use as a systemic drug in the treatment of allergic rhinitis and urticaria/pruritus in July 2000 and January 2002, respectively, and is marketed by Tanabe Seiyaku Co., Ltd. under the brand name TALION(R). ...

Separate Sets of Research Show Treatment Improved Quality of Life in as Early as Three Weeks; Patient Adherence to Medication is Multifactorial

... pain (14% vs. 8%) and nausea (13% vs. 15%); for the maintenance of remission of UC, the most frequent adverse events were headache (50% vs. 50%), rhinitis (42% vs. 36%), diarrhea (35% vs. 50%), abdominal pain (32% vs. 44%) and flatulence (24% vs. 30%). Asacol is contraindicated in patients with ...

CYT003-QbG10 to treat allergy to be presented at the Congress of the European Academy of Allergology and Clinical Immunology (EAACI), June 9-13, 2007

... to dust mites. Furthermore, two placebo-controlled phase IIa studies with CYT003-QbG10 delivered positive results in patients suffering from allergic rhinitis due to grass pollen allergy and house dust mite allergy. CYT003-QbG10 is currently being studied in clinical trials for the treatment of ...

Inspire Announces Presentations at Two European Scientific Conferences

... Poster and brief oral presentation on Tuesday, June 12, 2007 -- Treatment with Bilastine Improves Symptoms in Patients with Seasonal Allergic rhinitis (Phase 3 Study Comparing the Efficacy and Safety of Once Daily Bilastine with Desloratadine and Placebo for the Treatment of Seasonal ...

Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis

... Roughly 60% of those continue to have AD also in adulthood2. Children with AD are at greater risk for developing other allergic diseases like rhinitis or asthma later in life. AD is characterized by a hypersensitivity reaction occurring in the skin that causes chronic inflammation and renders the ...
Other Contents
(Date:12/10/2014)... 9, 2014 CIE San Diego has launched ... the connective tissue that enhances care coordination among social ... share client-level information; earned a second $1 million grant ... serving seniors aging in community and; will be recognized ... 11 th 4-6p. CIE San Diego ...
(Date:12/4/2014)... PALM BEACH GARDENS, Fla. , Dec. 3, ... identity management solutions, today announced that its DigitalPersona ... 4500 fingerprint readers have been deployed throughout ... Carolina , South Carolina ... network headquartered in Southern Pines, North ...
(Date:11/21/2014)... Strict laws against distracted driving and the ... American and European automotive sector towards gesture recognition technologies. ... that are intuitive and able to retrieve information with ... New analysis from Frost & Sullivan,s Strategic ... Europe and North America ...
Breaking Biology News(10 mins):Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4
(Date:12/26/2014)... 2014 India Network Foundation, a non-profit ... USA, announced today a new version of “ EasySelect ... the right plan for their visiting parents. The technology ... the selection process when choosing an insurance plan by ... only a few clicks. Many elderly Asian Indian parents ...
(Date:12/26/2014)... (PRWEB) December 26, 2014 DW-InductionHeating.com (DaWei ... in designing, researching and developing, producing and marketing of ... of the business announces their new series of ... manager of the company, induction brazing refers ... a special filler material and heat. The manager says ...
(Date:12/25/2014)... The microscopy market is estimated to ... $5,756.0 million by 2019. Optical microscopy is the ... microscopes product segment is expected to show the ... focus on nanotechnology, technological advancements, and increasing federal ... , Get Full Copy of Report @ ...
(Date:12/25/2014)... (PRWEB) December 26, 2014 ... BambooFlooringChina.com combines beauty, strength and durability. Today, the ... promotion, which is valid until Jan. 30, 2015. ... grain of traditional hardwood. BambooFlooringChina.com is a well-known ... help consumers worldwide to find a reliable bamboo ...
(Date:12/25/2014)... 26, 2014 The report “TS-1 (Colorectal ... on the current treatment landscape, unmet needs, current pipeline ... is an anti-cancer drug which is typically used for ... also used for treating gastric cancer and pancreatic cancer. ... The drug was first approved in 1999 in Japan ...
Breaking Medicine News(10 mins):Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 3Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3
Other TagsOther Tags